Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 5/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | REN | P00797 | 8/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 8/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1835462 | 0.88 | ALDH1A1 (0.36) | OPRL1ALDH1A1OPRM1RAB9ATSHR | |
| SCHEMBL11972841 | 0.86 | OPRL1 (0.41) | OPRL1ALDH1A1OPRM1RAB9AREN | |
| SCHEMBL11991804 | 0.85 | OPRL1 (0.35) | OPRL1ALDH1A1RAB9ATSHRSMN1; SMN2 | |
| SCHEMBL11972554 | 0.81 | OPRL1 (0.43) | OPRL1ALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL1805377 | 0.75 | ERN1 (0.40) | OPRL1ALDH1A1RAB9AMEN1KMT2A | |
| SCHEMBL1808442 | 0.74 | ALDH1A1 (0.39) | ALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL1810586 | 0.74 | OPRL1 (0.37) | OPRL1ALDH1A1OPRM1REN | |
| SCHEMBL11972717 | 0.73 | ALDH1A1 (0.34) | OPRL1ALDH1A1RAB9AMEN1KMT2A | |
| SCHEMBL1808978 | 0.72 | ALDH1A1 (0.37) | ALDH1A1RAB9ATSHRMEN1KMT2A | |
| SCHEMBL1805087 | 0.71 | CYP2A13 (0.48) | OPRL1ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2501704-B1 | Spiropiperidine compounds as oral-1 receptor antagagonisten | LILLY CO ELI (US) | 2013-09-18 | — | — | EP | disclosed |
| EP-2501704-A1 | SPIROPIPERIDINE COMPOUNDS AS ORL-1 RECEPTOR ANTAGONISTS | Eli Lilly and Company (US) | 2012-09-26 | — | — | EP | disclosed |
| US-20120214784-A1 | SPIROPIPERIDINE COMPOUNDS AS ORL-1 RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2012-08-23 | — | — | US | disclosed |
| WO-2011060217-A1 | SPIROPIPERIDINE COMPOUNDS AS ORL-1 RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2011-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120214784-A1 | SPIROPIPERIDINE COMPOUNDS AS ORL-1 RECEPTOR ANTAGONISTS | OPRL1, ORMDL3, OGFRL1 | OPRL1 1/4885ALDH1A1 509/4885OPRM1 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.